Capecitabine

Researchers are evaluating the effectiveness of combining electroacupuncture with self-administered acupressure and doctor-prescribed treatments to prevent Hand-Foot Syndrome (HFS) caused by the chemotherapy drug capecitabine. The trial focuses on patients with malignant tumors, including breast and gastrointestinal cancers, who are undergoing oral capecitabine treatment. The goal is to improve patients' quality of life during chemotherapy by exploring this combined preventive approach. Participants are randomly assigned to one of two groups: one receiving true electroacupuncture and true self-administered acupressure along with doctor-prescribed medications (oral celecoxib, topical diclofenac, and other skin protectants), and the other receiving sham electroacupuncture and sham self-administered acupressure with the same doctor-prescribed treatment. Electroacupuncture is given twice during the first week of each treatment cycle, with electrical stimulation lasting 30 minutes. The self-administered acupressure is performed in weeks two and three of each cycle, pressing specific points for three minutes each. The sham group receives minimal needle insertion at non-acupuncture points without electrical stimulation or "deqi" sensation. Participants are monitored from the start of capecitabine treatment through 12 weeks after treatment ends. Researchers record capecitabine dosage, HFS severity, onset time, and symptom duration. They also use the HFS-14 questionnaire at each cycle to assess patient condition. The main outcome measured is the incidence rate of HFS comparing the two groups. This trial is blinded for participants, evaluators, investigators, and statisticians to ensure unbiased results.

Researchers are evaluating the effectiveness and safety of two first-line treatments for patients with metastatic left-sided colorectal cancer who have wild-type RAS and BRAF genes. This phase 2, randomized study compares the combination of mCapOX plus cetuximab against mFOLFOX6 plus cetuximab in this specific patient group. The goal is to understand which treatment better controls the cancer without it progressing over time. Participants will be randomly assigned to one of two treatment groups. One group receives mCapOX plus cetuximab, which includes capecitabine taken orally twice daily for seven days, oxaliplatin given intravenously on day 1, and cetuximab administered intravenously every two weeks. The other group receives mFOLFOX6 plus cetuximab, consisting of intravenous oxaliplatin, leucovorin, a bolus of fluorouracil on day 1, a continuous fluorouracil infusion for 46 hours, and cetuximab every two weeks. Treatments continue according to the study schedule to compare their effects. During the study, participants will undergo evaluations to track progression-free survival at nine months, which measures the length of time the cancer does not worsen. Researchers will monitor patient health through clinical assessments, laboratory tests, and imaging to evaluate tumor response and safety. The study requires participants to have good performance status and meet specific laboratory criteria to ensure they can safely receive the treatments, with ongoing monitoring throughout the study period.

Researchers are evaluating the safety and effectiveness of a drug combination called Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) together with Cadonilimab for treating advanced pancreatic ductal adenocarcinoma in patients who have not received previous systemic treatment. This is a Phase II, single-center study focusing on patients with locally advanced or metastatic pancreatic cancer. Participants will receive a regimen that includes Nanoliposomal Irinotecan, Oxaliplatin, Capecitabine, and Cadonilimab. These medications will be given regularly as part of the treatment plan. The study involves only one group receiving this combination, aiming to assess the response rate and safety over time. During the study, patients will undergo assessments to measure how the cancer responds to the treatment, including imaging based on standard criteria (RECIST 1.1). Safety and organ function will be monitored, and participants must meet specific health and performance standards to join. The main outcome measured is the Objective Response Rate over two years, reflecting the proportion of patients whose tumors shrink or disappear with treatment.

Researchers are investigating the use of multi-target radiotherapy combined with a PD-1 monoclonal antibody and capecitabine maintenance therapy in treating patients with oligometastatic nasopharyngeal carcinoma. This is a single-arm, multicenter, prospective, open-label phase II clinical trial focused on evaluating the effectiveness and safety of this combination treatment. The study also aims to explore potential genetic biomarkers and develop evaluation and prediction models to identify patients who may benefit most from this therapy. The treatment involves radiotherapy performed 3 to 6 weeks after the end of first-line treatment, including conventional fractionated radiotherapy for the primary tumor and cervical lymph node metastases, and stereotactic body radiotherapy (SBRT) for distant organ metastases. Immunotherapy with a PD-1 inhibitor is administered throughout the trial until withdrawal or completion. Capecitabine is given as a maintenance therapy combined with the PD-1 inhibitor starting 3 to 6 weeks after radiotherapy. Participants will undergo regular assessments to monitor progression-free survival and overall survival over two years, as well as duration of response and safety. Researchers will evaluate clinical outcomes along with genetic markers. The study requires informed consent and cooperation with follow-up visits, with a focus on safety monitoring and efficacy during the treatment and observation periods.

Researchers are evaluating the combination of UTD1 and capecitabine in women aged 18 to 70 with metastatic HER2-negative breast cancer that has spread to the brain. This study is a single-arm, multicenter, open-label clinical trial aiming to assess the effectiveness and safety of this treatment in patients who have measurable brain lesions and meet specific health criteria. The study focuses on outcomes including the response rate of brain metastases within one year. Participants receive UTD1 at a dose of 30 mg/m2 daily on days 1 to 5 of each 21-day cycle. Capecitabine is administered orally at 2000 mg/m2 per day, divided into two doses from days 1 to 14, also on a 21-day cycle. Treatment continues according to the protocol, with monitoring for response and side effects throughout the study period. During the study, patients undergo brain MRI scans to evaluate the size and progression of brain metastases, along with routine blood tests to monitor liver, kidney, and blood function. Researchers track the central nervous system objective response rate from enrollment until disease progression or up to one year. Participants must be able to follow treatment schedules and attend follow-up visits, with safety and effectiveness continuously assessed throughout the trial.

Researchers are evaluating a treatment regimen combining XELOX chemotherapy, Bevacizumab, and Tislelizumab for patients with metastatic colorectal adenocarcinoma that is RAS-mutated and of the MSS/pMMR type. This Phase II study aims to determine the safety and effectiveness of this combination in transforming resistant colorectal cancer into a more treatable "hot tumor" by combining anti-vascular therapy, chemotherapy, and immunotherapy. Participants will receive a regimen including Tislelizumab, Bevacizumab, Oxaliplatin, and Capecitabine on a regular schedule. This combination treatment is designed as a first-line therapy for patients whose cancer cannot be surgically removed. The study focuses on monitoring the response to this combined approach. During the study, patients will be assessed for their cancer response over two years using the Objective Response Rate (ORR). Researchers will monitor safety, organ function, and overall health throughout treatment. Participants must be able to swallow oral medications and have measurable cancer lesions. The trial includes careful follow-up to evaluate effectiveness and side effects over the treatment period.